The week in pharma: action, reaction and insight – week to December 16, 2022

19 December 2022

By Barbara Obstoj-Cardwell. Editor

Last week saw the announcements of the biggest pharmaceutical M&A and licensing deals of the year. US biotech giant Amgen, which will soon be facing competition from biosimilars, agreed to fork out around $28 billion to acquire Horizon Therapeutics. Another US biotech, Clovis Oncology, has finally thrown in the towel, filing for Chapter 11 bankruptcy, and a “stalking-horse” deal with Novartis. Japan’s largest drugmaker Takeda announced a licensing deal with Nimbus Therapeutics for the latter’s autoimmune candidate NDI-034858, re-coded TAK-279, paying a massive $4 billion upfront.

Horizon acquisition key considerations

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK